Novo data buttress its oral semaglutide case, this time in kidney-impaired patients

Novo Nordisk
Novo Nordisk's oral semaglutide topped placebo at reducing hbA1c among kidney-impaired patients. (Novo Nordisk)

The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles.

Monday, the Danish drugmaker said that in a phase 3a trial of Type 2 diabetes patients with kidney impairment, the prospect topped placebo at significantly reducing hbA1c, a common blood glucose measure, at week 26. And those in the study’s semaglutide arm recorded larger weight-loss numbers, too.

"Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options, and if approved oral semaglutide represents an efficacious new solution for these people," Novo’s chief science officer, Mads Krogsgaard Thomsen, said in a statement.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Novo Nordisk trumpets more Januvia-topping data for oral semaglutide

The data add to a wealth Novo has already generated for the up-and-comer. In June, the company rolled out favorable results pitting semaglutide against fellow Novo GLP-1 drug Victoza and Merck mammoth Januvia, a DPP-4 therapy.

But all of that clinical evidence will be key for Novo as it pushes its pill into a competitive GLP-1 market, which features stiff competition from Eli Lilly in addition to Novo’s own options. And it’ll no doubt also come into play when Novo sits down to choose a price for semaglutide, a decision that could go a few different ways.

RELATED: Novo has a big pricing decision to make with semaglutide. Which way will it go?

Novo has to “make some technical considerations,” around pricing, CEO Lars Fruergaard Jørgensen said in a recent interview, adding, “Do we price as a GLP-1, or do we price more as a tablet, or somewhere in between?”

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.